• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

甲磺酸伊马替尼治疗继发的迟发性单侧视盘水肿。

Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate.

作者信息

Napolitano Mariasanta, Santoro Marco, Mancuso Salvatrice, Carlisi Melania, Raso Simona, Tarantino Giuseppe, Accurso Vincenzo, Siragusa Sergio

机构信息

Hematology Division University Hospital Policlinico "Paolo Giaccone" via del Vespro 129 Palermo 90127 Italy.

出版信息

Clin Case Rep. 2017 Aug 15;5(10):1573-1575. doi: 10.1002/ccr3.1137. eCollection 2017 Oct.

DOI:10.1002/ccr3.1137
PMID:29026547
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5628210/
Abstract

Prompt ophthalmology evaluation and immediate imatinib suspension should be suggested at any time of tyrosine kinase inhibitor therapy in patients with visual deficit, as it may be a clinical manifestation of optic disk edema, and suspension may help in prompt recovery.

摘要

对于接受酪氨酸激酶抑制剂治疗且出现视力减退的患者，在酪氨酸激酶抑制剂治疗的任何阶段，均应建议进行眼科及时评估并立即停用伊马替尼，因为这可能是视盘水肿的临床表现，停用可能有助于迅速恢复。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be14/5628210/942f58504d50/CCR3-5-1573-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be14/5628210/942f58504d50/CCR3-5-1573-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be14/5628210/942f58504d50/CCR3-5-1573-g001.jpg

相似文献

1
Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate.甲磺酸伊马替尼治疗继发的迟发性单侧视盘水肿。
Clin Case Rep. 2017 Aug 15;5(10):1573-1575. doi: 10.1002/ccr3.1137. eCollection 2017 Oct.
2
Imatinib mesylate (Gleevec) induced unilateral optic disc edema.甲磺酸伊马替尼（格列卫）诱发单侧视盘水肿。
Optom Vis Sci. 2012 Oct;89(10):e16-22. doi: 10.1097/OPX.0b013e318269111d.
3
Periorbital edema secondary to imatinib mesylate.甲磺酸伊马替尼继发的眶周水肿
Clin Ophthalmol. 2010 May 14;4:427-31. doi: 10.2147/opth.s8521.
4
Spotlight on imatinib mesylate in chronic myeloid leukemia.聚焦甲磺酸伊马替尼治疗慢性髓性白血病
BioDrugs. 2004;18(3):207-10. doi: 10.2165/00063030-200418030-00009.
5
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.甲磺酸伊马替尼用于慢性髓性白血病：一线治疗及长期疗效
Expert Rev Anticancer Ther. 2016;16(3):273-8. doi: 10.1586/14737140.2016.1151356.
6
Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.甲磺酸伊马替尼治疗慢性粒细胞白血病患者的血液病理学和细胞遗传学发现：2.5年经验
Vojnosanit Pregl. 2010 Oct;67(10):802-6. doi: 10.2298/vsp1010802c.
7
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.美国食品药品监督管理局药品批准总结：甲磺酸伊马替尼（STI571；格列卫）片剂从加速批准转为完全批准。
Clin Cancer Res. 2005 Jan 1;11(1):12-9.
8
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的分子研究。
Semin Hematol. 2001 Jul;38(3 Suppl 8):15-21. doi: 10.1016/s0037-1963(01)90113-1.
9
Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.伊马替尼治疗慢性髓性白血病患者的皮肤不良反应：六年随访。
Eur J Dermatol. 2016 Apr 1;26(2):133-7. doi: 10.1684/ejd.2015.2684.
10
Imatinib mesylate-induced lichenoid drug eruption.甲磺酸伊马替尼诱发苔藓样药疹。
Cutis. 2017 Mar;99(3):189-192.

引用本文的文献

1
Side Effects of Novel Anticancer Drugs on the Posterior Segment of the Eye: A Review of the Literature.新型抗癌药物对眼后段的副作用：文献综述
J Pers Med. 2024 Dec 19;14(12):1160. doi: 10.3390/jpm14121160.
2
Neuro-ophthalmic complications of modern anti-cancer drugs.现代抗癌药物的神经眼科并发症。
Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2269-2281. doi: 10.1007/s00417-023-06350-4. Epub 2024 Feb 12.
3
Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.靶向癌症治疗及其眼部副作用：综述

本文引用的文献

1
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.欧洲白血病网关于慢性髓性白血病治疗管理及不良事件避免的建议
Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28.
2
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.欧洲白血病网络关于慢性髓性白血病管理的建议：2013 年版。
Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
3
Imatinib mesylate (Gleevec) induced unilateral optic disc edema.
J Immunother Precis Oncol. 2021 Feb 25;4(1):6-15. doi: 10.36401/JIPO-20-21. eCollection 2021 Feb.
甲磺酸伊马替尼（格列卫）诱发单侧视盘水肿。
Optom Vis Sci. 2012 Oct;89(10):e16-22. doi: 10.1097/OPX.0b013e318269111d.
4
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.比较接受伊马替尼长期治疗的慢性髓性白血病患者与普通人群的健康相关生活质量。
Blood. 2011 Oct 27;118(17):4554-60. doi: 10.1182/blood-2011-04-347575. Epub 2011 Jul 12.
5
Optic disc edema as a possible complication of Imatinib mesylate (Gleevec).视盘水肿作为甲磺酸伊马替尼（格列卫）的一种可能并发症。
Jpn J Ophthalmol. 2008 Jul-Aug;52(4):331-333. doi: 10.1007/s10384-008-0561-7. Epub 2008 Sep 5.
6
Visual disturbance due to retinal edema as a complication of imatinib.
Leukemia. 2004 Jun;18(6):1138-9. doi: 10.1038/sj.leu.2403364.
7
Ocular side-effects associated with imatinib mesylate (Gleevec).与甲磺酸伊马替尼（格列卫）相关的眼部副作用。
J Ocul Pharmacol Ther. 2003 Aug;19(4):371-5. doi: 10.1089/108076803322279426.
8
Practical management of patients with chronic myeloid leukemia receiving imatinib.接受伊马替尼治疗的慢性髓性白血病患者的实际管理
J Clin Oncol. 2003 Apr 15;21(8):1637-47. doi: 10.1200/JCO.2003.11.143. Epub 2003 Mar 13.
9
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.伊马替尼与干扰素和小剂量阿糖胞苷治疗新诊断慢性期慢性髓性白血病的比较
N Engl J Med. 2003 Mar 13;348(11):994-1004. doi: 10.1056/NEJMoa022457.
10
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.一种BCR-ABL酪氨酸激酶特异性抑制剂在慢性髓性白血病中的疗效与安全性
N Engl J Med. 2001 Apr 5;344(14):1031-7. doi: 10.1056/NEJM200104053441401.